Brought to you by Wiley
Login | Register
Ezine News Education Links
Webinars Podcasts Books & Journals Jobs Products Conferences Classifieds
Perceptive Informatics Expands Nuclear Imaging Capabilities for Cardiology Trials
[November 20, 2009 PR Newswire]

BOSTON, Nov 17, 2009 /PRNewswire-FirstCall via COMTEX

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced that it has expanded its leading medical imaging capabilities with advanced nuclear imaging functionality for cardiology clinical trials. Perceptive has incorporated into its medical imaging technologies components of Hermes Medical Solutions Nuclear Medicine Software Suite and INVIA's Corridor4DM, a solution for nuclear cardiac quantification and imaging. The solutions allow Perceptive to better integrate several imaging modalities, including Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Multi Gated Acquisition Scan (MUGA) to enhance electronic processing, review, analysis, reporting, and archiving of medical images for cardiology trials.

The Hermes Medical Solutions Nuclear Medicine Software Suite provides the ability to display and reconstruct raw data sets using both back-projection and iterative methods for quantitative analysis. These solutions allow Perceptive to accept images from any scanner and assemble them into a standardized, consistent format for processing and review. Corridor4DM from INVIA offers quantification, review, and reporting of cardiac perfusion, function, and anatomy in 3-D. The system provides advanced processing algorithms and image display for greater diagnostic accuracy and quality assurance. These enhancements further expand Perceptive's capabilities for medical imaging-based cardiology trials, which include the use of DigiView, a specialized echocardiography image management and reporting system for cardiac function assessment.

"Perceptive is committed to continually incorporating innovative state-of-the-art technologies into our capabilities to help biopharmaceutical companies further improve the use of medical imaging as a surrogate endpoint, or biomarker. Key goals in expanding our capabilities with this advanced nuclear imaging functionality are to help customers make earlier safety and efficacy assessments and better decisions about their compounds in order to bring new cardiovascular treatments to patients sooner," said Kenneth G. Faulkner, Ph.D., Vice President of Medical Imaging, Perceptive Informatics.

The incorporation of technologies from Hermes Medical Solutions and INVIA supplements the medical imaging capabilities of Perceptive Informatics by providing solutions tailored for cardiology related trials, including specialized PET, SPECT, and MUGA techniques. The Medical Imaging Group of Perceptive Informatics offers a full range of capabilities in the application of imaging techniques from early clinical development through peri-approval studies. The medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, neurology, rheumatology, cardiology, and endocrinology. Perceptive's medical imaging technologies are fully validated and in compliance with regulatory guidelines.

About Perceptive Informatics

Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive's eClinical Suite visit: www.perceptive.com.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has more than 9,130 employees. For more information about PAREXEL International visit www.PAREXEL.com.


Copyright (C) 2009 PR Newswire. All Rights Reserved